CVS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

103.80B

+6.23%

0.991

-16.72%

96.27B

+1.78%

2.257

+0.32%

101.10B

+2.21%

1.901

+5.04%

Estimates Revision

The market is revising Upward the revenue expectations for CVS Health Corporation (CVS) for FY2025, with the revenue forecasts being adjusted by 1.36% over the past three months. During the same period, the stock price has changed by 8.48%.

Revenue Estimates for FY2025

Revise Upward

+1.36%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+3.6%

In Past 3 Month

Stock Price

Go Up

+8.48%

In Past 3 Month

16 Analyst Rating

Wall Street analysts forecast CVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CVS is 90.53 USD with a low forecast of 75.00 USD and a high forecast of 102.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

15 Buy

1 Hold

0 Sell

Strong Buy

Current: 79.690

Low

75.00

Averages

90.53

High

102.00

Current: 79.690

Low

75.00

Averages

90.53

High

102.00

Bernstein

Market Perform

maintain

$86 -> $87

2025-12-12

New

Reason

Bernstein

Price Target

$86 -> $87

2025-12-12

New

maintain

Market Perform

Reason

Bernstein raised the firm's price target on CVS Health to $87 from $86 and keeps a Market Perform rating on the shares following overall a very positive Investor Day event. The firm cites increased confidence in quality and depth of management teams, and reinforcement of the quality and market leadership of leading companies.

Baird

Outperform

maintain

$82 -> $92

2025-12-10

New

Reason

Baird

Price Target

$82 -> $92

2025-12-10

New

maintain

Outperform

Reason

Baird raised the firm's price target on CVS Health to $92 from $82 and keeps an Outperform rating on the shares. The firm updated its model and believes its bull thesis remains intact.

Mizuho

Ann Hynes

Outperform

maintain

$88 -> $95

2025-12-10

New

Reason

Mizuho

Ann Hynes

Price Target

$88 -> $95

2025-12-10

New

maintain

Outperform

Reason

Mizuho analyst Ann Hynes raised the firm's price target on CVS Health to $95 from $88 and keeps an Outperform rating on the shares, telling investors that the company provided "several positive updates" at its bi-annual investor day, including updated 2025 guidance, detailed 2026 guidance, and a raised long-term earnings growth outlook. CVS is the top pick in the analyst's coverage universe, the analyst noted.

Truist

Buy

maintain

$95 -> $98

2025-12-10

New

Reason

Truist

Price Target

$95 -> $98

2025-12-10

New

maintain

Buy

Reason

Truist raised the firm's price target on CVS Health to $98 from $95 and keeps a Buy rating on the shares. The firm remains bullish on CVS post an upbeat Investor Day highlighting the company's differentiated collection of assets, strong positioning and opportunities across segments, alongside the announced launch of a centralized engagement platform in FY26, the analyst tells investors in a research note. Brisk cash flow and ongoing balance sheet improvement underpins continued core growth investment, the firm added.

UBS

Kevin Caliendo

Buy

maintain

$96 -> $97

2025-12-10

New

Reason

UBS

Kevin Caliendo

Price Target

$96 -> $97

2025-12-10

New

maintain

Buy

Reason

UBS analyst Kevin Caliendo raised the firm's price target on CVS Health to $97 from $96 and keeps a Buy rating on the shares. The current EPS compound annual growth rate of mid-teens growth through 2028E does not contemplate any meaningful capital deployment, suggesting that CVS could have a positive upside/downside skew to earnings for 2027 and beyond, the analyst tells investors in a research note. UBS remains optimistic that Q4 has potentially more upside to EPS.

Barclays

Overweight

maintain

$87 -> $93

2025-12-10

New

Reason

Barclays

Price Target

$87 -> $93

2025-12-10

New

maintain

Overweight

Reason

Barclays raised the firm's price target on CVS Health to $93 from $87 and keeps an Overweight rating on the shares following the investor day. The company guided to mid-teens earnings growth through 2028, which includes margin improvement at Aetna and Care Delivery, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for CVS Health Corp (CVS.N) is 11.56, compared to its 5-year average forward P/E of 10.16. For a more detailed relative valuation and DCF analysis to assess CVS Health Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

10.16

Current PE

11.56

Overvalued PE

11.57

Undervalued PE

8.76

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

9.07

Current EV/EBITDA

10.10

Overvalued EV/EBITDA

9.95

Undervalued EV/EBITDA

8.19

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

0.30

Current PS

0.25

Overvalued PS

0.39

Undervalued PS

0.21

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress areSelling! The selling amount has increased306.25%over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CVS News & Events

Events Timeline

No data

News

8.0

12-13SeekingAlpha

House Republicans unveil health care legislation lacking increased subsidies

6.5

12-11Barron's

Shift Your Attention from the S&P 500's Market Capitalization to Revenue Analysis

8.5

12-11Newsfilter

CVS Offers Measles Vaccine at Over 200 Locations in South Carolina

People Also Watch

Frequently Asked Questions

What is CVS Health Corp (CVS) stock price today?

The current price of CVS is 79.69 USD — it has increased 0.34 % in the last trading day.

What is CVS Health Corp (CVS)'s business?

CVS Health Corporation is a health solutions company. The Company's segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, PDPs and Medicaid health care management services. Health Services segment provides a full range of pharmacy benefit management (PBM) solutions through its CVS Caremark operations and delivers health care services in its medical clinics, virtually, and in the home. Pharmacy & Consumer Wellness segment dispenses prescriptions in its CVS Pharmacy retail locations and through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, diagnostic testing and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise.

What is the price predicton of CVS Stock?

What is CVS Health Corp (CVS)'s revenue for the last quarter?

CVS Health Corp revenue for the last quarter amounts to 102.87B USD, increased 7.80 % YoY.

What is CVS Health Corp (CVS)'s earnings per share (EPS) for the last quarter?

CVS Health Corp. EPS for the last quarter amounts to -3.13 USD, decreased -4571.43 % YoY.

What changes have occurred in the market's expectations for CVS Health Corp (CVS)'s fundamentals?

How many employees does CVS Health Corp (CVS). have?

CVS Health Corp (CVS) has 300000 emplpoyees as of December 15 2025.

What is CVS Health Corp (CVS) market cap?

Today CVS has the market capitalization of 101.16B USD.